Researchers analyzed data from many clinical trials to compare how well different approved systemic medications work for adults with moderate-to-severe atopic dermatitis, also known as eczema. They looked at outcomes like achieving 75% or 90% clearer skin, having clear or almost clear skin according to a doctor's assessment, and meaningful itch reduction. The analysis included data from over 16,000 patients.
The main finding was that among the medications studied, upadacitinib at a 30 mg dose consistently ranked highest for the probability of achieving each of these positive clinical outcomes. The analysis also found that some other medications, like dupilumab and stapokibart at certain doses, did not show a statistically significant difference in effectiveness from each other.
It is very important to understand that this was a network meta-analysis. This means the researchers compared results from many separate studies, not from a single trial where patients were randomly assigned to different medications and directly compared. The safety profiles of these drugs were not compared in this analysis. Because of this indirect comparison method, the results should be seen as suggesting a ranking, not as definitive proof. Direct, head-to-head clinical trials are needed to confirm which medication is most effective and safest for patients.